Lung cancer--time to move on from chemotherapy.
暂无分享,去创建一个
[1] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[2] K. Mori,et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.
[3] Y. Miller,et al. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. , 2001, Journal of the National Cancer Institute.
[4] J. Crowley,et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] S. Cummings,et al. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Taylor Murray,et al. Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.
[7] S. Moss,et al. Lung cancer screening , 2000, Cancer.
[8] A. Kraus,et al. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] U. Pastorino,et al. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] O. Miettinen,et al. Early Lung Cancer Action Project: overall design and findings from baseline screening , 1999, The Lancet.
[11] R. Simon,et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M Paesmans,et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Ettinger,et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.